Activity Overview
A growing number of available obesity medications offer a variety
of indications, mechanisms, and clinical uses—and more are under investigation.
Keeping track of agents that fit a particular patient is a growing challenge
for clinicians who manage obesity. In this program, 2
experts unpack recent guideline recommendations and clinical trial data for
approved and emerging obesity medications, then apply that evidence to a
patient case to model how to build an individualized, guideline-informed
treatment plan.
Target Audience
This
educational activity is directed toward endocrinologists, diabetes specialists,
dietitians, primary care physicians, nurse practitioners, physician assistants,
and nurses. Other health care professionals involved in the care of patients
with obesity are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Outline guideline recommended best practices for the management of obesity and associated comorbidities
- Evaluate clinical trial efficacy and safety data for current and emerging therapies for the management of obesity
- Implement recommended procedures to prevent, minimize, or manage adverse events associated with anti-obesity medications (AOMs)
- Design individualized, comprehensive, guideline-supported AOM-based treatment plans that optimize short- and long-term clinical outcomes while improving health-related quality of life in patients with obesity
Fatima Cody Stanford, MD, MPH, MPA, MBA, MACP, FAAP, FAHA, FAMWA, FTOS
Mass General Brigham and Harvard Medical School
Boston, MA
Disclosures: Advisor,
Consultant, Fee for Service Recipient: AbbVie,
Amgen, AstraZeneca, Boehringer Ingelheim, Clearmind Medicine, Currax, Doximity,
Eli Lilly, Empros Pharma, L'Oreal, MelliCell, Novo Nordisk, Pfizer; Grant/Research Funding: Eli Lilly
Robert Busch, MD
Albany Medical Center
Albany, NY
Disclosures: Speaker’s Bureau: Ascendis, Amgen, Bayer, Eli Lily, Madrigal, Novo Nordisk Grant / Research Funding: Abbot, Lilly, Novo Nordisk
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here